These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1701163)

  • 1. Targeted killing of yeast expressing a HIV-1 peptide by antibody-conjugated glucose oxidase and horseradish peroxidase.
    Chouchane L; Bringman T; Barbier S; Traincard F; Strosberg AD
    Immunol Lett; 1990 Sep; 25(4):359-65. PubMed ID: 1701163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1.
    VanCott TC; Loomis LD; Redfield RR; Birx DL
    J Immunol Methods; 1992 Feb; 146(2):163-76. PubMed ID: 1538140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
    Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping.
    Ohlin M; Broliden PA; Danielsson L; Wahren B; Rosen J; Jondal M; Borrebaeck CA
    Immunology; 1989 Nov; 68(3):325-31. PubMed ID: 2480328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein.
    Sastry KJ; Arlinghaus RB
    AIDS; 1991 Jun; 5(6):699-707. PubMed ID: 1715718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine specificity of the murine antibody response to HIV-1 gp160 determined by synthetic peptides which define selected epitopes.
    Wolf H; Warren RQ; Stunz GW; Shuler KR; Kanda P; Kennedy RC
    Mol Immunol; 1992; 29(7-8):989-98. PubMed ID: 1378936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.
    Langedijk JP; Back NK; Kinney-Thomas E; Bruck C; Francotte M; Goudsmit J; Meloen RH
    Arch Virol; 1992; 126(1-4):129-46. PubMed ID: 1381908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates.
    Nakamura GR; Byrn R; Rosenthal K; Porter JP; Hobbs MR; Riddle L; Eastman DJ; Dowbenko D; Gregory T; Fendly BM
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1875-85. PubMed ID: 1283308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
    Shirai M; Pendleton CD; Berzofsky JA
    J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential V beta usage by cytotoxic T cells cross-reactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction.
    Shirai M; Vacchio MS; Hodes RJ; Berzofsky JA
    J Immunol; 1993 Aug; 151(4):2283-95. PubMed ID: 7688397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
    Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA
    AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
    Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T lymphocytes specific for HIV-1 gp160 antigen and synthetic P18IIIB peptide in an HLA-A11-immunized individual.
    Achour A; Lemhammedi S; Picard O; M'Bika JP; Zagury JF; Moukrim Z; Willer A; Beix F; Burny A; Zagury D
    AIDS Res Hum Retroviruses; 1994 Jan; 10(1):19-25. PubMed ID: 8179960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope.
    Achour A; Picard O; Mbika JP; Willer A; Snart R; Bizzini B; Carelli C; Burny A; Zagury D
    Vaccine; 1993; 11(7):609-701. PubMed ID: 7688170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.
    Boyer V; Broly H; Souche S; Madaule P; Rossier J; Zagury D; Desgranges C
    Clin Exp Immunol; 1991 Mar; 83(3):452-9. PubMed ID: 1706239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I- and class II-restricted T cells: not all T cells can respond to whole molecule stimulation.
    Moore RL; Fox BS
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):51-9. PubMed ID: 7678972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.